Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)
July 24, 2025 6:46 AM EDTCiti Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "We are opening a 90-day downside short-term view on SRPT. Our view is anchored on new and open questions surrounding Elevidys marketing approval in ambulatory Duchenne patients, the possibility of... More
